Results 21 to 30 of about 10,168 (235)
Role of immune checkpoint blockers in patients with EGFR mutation. [PDF]
Transl Lung Cancer Res, 2018 Ward J, Morgensztern D.
europepmc +4 more sources
Emerging Therapeutic Agents for Colorectal Cancer
Molecules, 2021 There are promising new therapeutic agents for CRC patients, including novel small-molecule inhibitors and immune checkpoint blockers. We focused on emerging CRC’s therapeutic agents that have shown the potential for progress in clinical practice.
Marianna Nalli +4 more
doaj +1 more source
A tumor-targeted immune checkpoint blocker [PDF]
Proceedings of the National Academy of Sciences, 2019 Significance Current immune checkpoint inhibitors are not tumor specific and induce systemic immune activation in other tissues and organs. Combination immunotherapies further amplify these toxicities, which limit their clinical application.
Yuhan, Zhang +11 more
openaire +2 more sources
Role of inflammasome activation in tumor immunity triggered by immune checkpoint blockers [PDF]
Clinical and Experimental Immunology, 2020 Summary Immune checkpoint blockers improve the overall survival of a limited number of patients among different cancers. Identifying pathways that influence the immunological and clinical response to treatment is critical to improve the therapeutic efficacy and predict clinical responses.
M Segovia +4 more
openaire +3 more sources
Frontiers in Oncology, 2022 Cervical cancer is one of the women-associated tumors that affects numerous people yearly. It is the fourth most common malignancy in women worldwide.
Haigang Ding +9 more
doaj +1 more source
Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer
OncoImmunology, 2023 Checkpoint blockade immunotherapy transforms many types of cancer; however, in the field of metastatic colorectal cancer, checkpoint blockers are only effective in microsatellite-unstable tumors, which represent only a minority of patients ...
Marion Thibaudin, Francois Ghiringhelli
doaj +1 more source
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers [PDF]
Clinical Cancer Research, 2016 Abstract Immunotherapy is currently transforming cancer treatment. Notably, immune checkpoint blockers (ICB) have shown unprecedented therapeutic successes in numerous tumor types, including cancers that were traditionally considered as nonimmunogenic. However, a significant proportion of patients do not respond to these therapies. Thus,
Roman M, Chabanon +5 more
openaire +2 more sources
Novel immune checkpoint blocker to treat Merkel cell carcinoma [PDF]
OncoImmunology, 2017 Over the past few years, immune checkpoint blockers (ICBs) have literally revolutionized the treatment of multiple tumors, including (but not limited to) melanoma, non-small cell lung carcinoma (NS...
Lorenzo Galluzzi, Guido Kroemer
openaire +3 more sources
Immune Checkpoint Inhibitors in Peripheral T-Cell Lymphoma
Frontiers in Pharmacology, 2022 Peripheral T-cell lymphomas (PTCLs) are highly heterogeneous and present significant treatment challenges. Immune checkpoint therapies, such as PD-1 and CTLA-4 inhibitors, have significantly changed the clinical management paradigm of tumors.
Xi Chen +3 more
doaj +1 more source
Nature Communications, 2022 Tumor loss of IFN-γ signalling is a major mechanism of resistance to immune checkpoint blockers. Here the authors report that melanoma cells with knockout of IFNγR1 show constitutive JAK1/2 activation and that the JAK1/2 inhibitor ruxolitinib can ...
Hongxing Shen +13 more
doaj +1 more source